Bijal Shah, MD, on CAR T-Cell Therapy in ALL
Bijal Shah, MD, of Moffitt Cancer Center, summarizes his presentation on the role of chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia (ALL), touching on its use in the front-line setting for newly diagnosed patients with high risk-features as well as in patients with relapsed or refractory disease. Dr. Shah also discusses the role of measurable residual disease, improving the duration of response after CAR T-cell therapy, how stem cell transplantation fits into this treatment paradigm, and ongoing/upcoming clinical trials in the space.